Privacy Watchdog Brings Sonobi into Compliance with Digital Advertising Privacy Best Practices

McLean, VA – December 14, 2023 - The Digital Advertising Accountability Program (DAAP) of BBB National Programs brought Sonobi, Inc., a leading advertising technology developer and digital advertiser, into compliance with the Digital Advertising Alliance’s (DAA) Self-Regulatory Principles for online interest-based advertising. 

Following a consumer complaint regarding ineffective opt-out experiences despite using industry-provided tools, DAAP investigated Sonobi's practices. The inquiry revealed that Sonobi is engaged in interest-based advertising (IBA) collection across non-affiliate websites, but that its technology did not respect opt-out signals as intended. Additionally, Sonobi’s privacy policy lacked a statement aligning with OBA self-regulatory principles in its section on opting out of Interest-Based Advertising.

DAAP conducted testing of Sonobi’s advertising technology, which revealed consistent overwriting of opt-out cookies, disregarding user preferences across multiple tests and devices indicating the ongoing IBA tracking despite user opt-outs, even after users set preferences via DAA and Network Advertising Initiative tools. Sonobi also shared user profile cookie contents with third-party IBA companies via cookie syncing servers, compromising opt-out choices. 

In response to DAAP’s inquiry, Sonobi immediately conducted a review of its compliance with the DAA Principles to identify areas that needed strengthening. Sonobi discovered an error in its advertising technology that affected the opt-out logic and resulted in Sonobi servers overwriting previously established opt-out preferences. 

Sonobi promptly corrected the error in their server’s response and DAAP found that Sonobi’s opt-out cookies now operate properly, allowing users to set an opt-out preference that remains and prevents further collection by Sonobi regardless of subsequent browsing activity. Sonobi also added a statement of adherence to the DAA Principles in its privacy policy. 

DAAP is satisfied with Sonobi’s response and its commitment to transparency and consumer choice, reflected by its expeditious action to rectify the matter. 

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of DAAP decisions, visit the DAAP Decisions and Guidance webpage.

 

Subscribe to the Ad Law Insights or Privacy Initiatives newsletters for an exclusive monthly analysis and insider perspectives on the latest trends and case decisions in advertising law and data privacy.

 

 

 

 

Latest Decisions

Decision

National Advertising Division Recommends Dr. Luke Healthcare Discontinue Treatment Claims for its Fungal Nail Renewal Product

New York, NY – July 24, 2024 – The National Advertising Division recommended Dr. Luke Healthcare discontinue certain claims for Dr. Luke’s Fungal Nail Renewal product, including health-related claims, natural claims, and claims that a doctor recommends the product or that it treats a medical condition.

Read the Decision Summary
Decision

National Advertising Division Finds Flag Image on Kendamil Infant Formula Packaging Conveys Supported Message about Products’ Origin

New York, NY – July 17, 2024 – In a Fast-Track SWIFT challenge, the National Advertising Division determined that use of a flag image on product packaging for Kendal Nutricare’s Kendamil infant formula reasonably conveys a supported message about the products’ origin. 

Read the Decision Summary
Decision

In National Advertising Division Case, GuruNanda Voluntarily Discontinues Claims Made through Influencers for Coconut Pulling Oil Products

New York, NY – July 16, 2024 – The National Advertising Division has closed a Fast-Track SWIFT challenge regarding claims that GuruNanda’s coconut pulling oil products can “naturally reverse a cavity” and “reverse cavities.” 

Read the Decision Summary
Decision

National Advertising Division Refers Health-Related Advertising Claims for Prolacta’s Human Milk Fortifier to Regulatory Agencies

New York, NY – July 15, 2024 – The National Advertising Division will refer advertising claims made by Prolacta Bioscience for its Human Milk Fortifier to the Federal Trade Commission (FTC) and Food and Drug Administration (FDA) for review.

Read the Decision Summary